| Project/Area Number |
24592515
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SAWADA Kenjiro 大阪大学, 医学系研究科, 講師 (00452392)
MABUCHI Seiji 大阪大学, 医学系研究科, 助教 (00452441)
ISOBE Aki 大阪大学, 医学系研究科, 助教 (60397619)
HASHIMOTO Kae 大阪大学, 医学系研究科, 助教 (90612078)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 卵巣癌 / 抗血管新生療法 / NF-κB シグナル / VEGF / 抗血管新生治療 / 分子標的治療 / NF-κBシグナル / PlGF |
|---|
| Outline of Final Research Achievements |
The improvement of outcome in patients with ovarian cancer by an anti-angiogenic therapy has been shown in large clinical trials. However, the only option currently available is the anti-VEGF-A antibody, which efficacy is limited. Therefore, we aim to develop a new anti-angiogenic drug for ovarian cancer. As NF-κB signaling has the potential to regulate several angiogenic factors including VEGF-A, we determined to identify the significance of NF-κB activation in ovarian cancer and to investigate the possibility of a novel NF-κB inhibitor as an anti-angiogenic drug. Immunohistochemical analyses using ovarian cancer tissues showed that NF-κB activation is an independent prognostic factor. A specific NF-κB inhibitor led to the inhibition of angiogenesis in vitro and in vivo. In a xenograft model, the treatment of NF-κB inhibitor significantly suppressed peritoneal dissemination. Anti-angiogenic therapy targeting NF-κB signaling is a potential future option to treat ovarian cancer.
|
